Global Partnerships Drive Progress: Biologics Contract Manufacturing Sees Over 61% Increase in Partnerships Post-COVID-19
The global biologics contract manufacturing market is estimated to reach over $19 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of ~9% during the forecast period.
The biologics contract manufacturing market, also known as the biopharmaceutical CMO market, is a dynamic and rapidly growing sector with a large number of players investing in research and development activities for developing new modalities, such as antibody drug conjugates, biosimilars, and cell and gene therapies. With the increased interest and gradual shift of investment from small molecule drugs to biologics, over the years, more than 250 biologic therapies and vaccines have been developed globally. Notably, biologics have higher success rates than conventional small-molecule drugs owing to lesser off-target toxicity of biologics, which is one of the key reasons of failures in small molecule drugs development. Given the ongoing scientific advancements and the rise of FDA-approved biologics, the pharmaceutical industry seems to be approaching the era of biologics. In fact, biopharmaceuticals are anticipated to play a significant role in shaping the pharmaceutical industry and will eventually serve as an integral part of traditional medicines. Moreover, the exuberant development of biologics has revolutionized the treatment of a range of therapeutic conditions, which has further contributed to the exponential growth in the current demand for biologic therapies. It is worth highlighting that numerous biologics manufacturers, including biologics CMOs, have adopted digital technologies in order to enhance their productivity and reliability of existing biologics related processes and facilities. In March 2023, Bristol Myers Squibb sent a selection of its protein-based medicines to the International Space Station with the aim to refine their production processes and improve the biomanufacturing of potent medicines.
However, the complexity of biologics, as well as the integration of emerging technologies, offer challenges for current good manufacturing practices (cGMP) for biologics. Some of the key concerns of contemporary innovators include rate of attrition of pipeline drugs / therapies, long development timelines, current facility limitations, regulatory and compliance-related issues, and inconsistencies related to the quality attributes of the final product. As a result, an increasing number of biopharmaceutical drug developers are relying on contract manufacturers that are well-equipped with expertise and advanced technologies for their GMP-based manufacturing requirements. These service providers offer end-to-end solutions, including bioprocess development and optimization, to shorten operational timelines and reduce the high costs associated with the production of complex biologic drugs. In addition, there are some manufacturers that particularly outsource various operations to tap into sophisticated facilities and know-how, particularly if contract manufacturing firms are utilizing cutting-edge technologies, such as software-driven robotics, to enhance manufacturing processes and mitigate the risks and constraints associated with manual methods. With outsourcing becoming increasingly accepted as a viable and beneficial business model within this field, the global market for biologics contract manufacturing is expected to witness remarkable growth during the forecast period.
Key Market Insights
This report features an extensive study of the current market landscape, market size and future opportunities associated with the biologics contract manufacturing market, during the given forecast period. Further, the market report highlights the efforts of various stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the biologics contract manufacturing market are briefly discussed below.
Growing Demand for Biologics
Biologics are the essential structural analogs of various biomolecules found in the human body. They are highly specific and have fewer side effects as compared to conventional pharmacological molecules. Thus, biologics exhibit enormous potential to target and eradicate the cause of a disease at the genetic level, which has resulted in the increased interest of various stakeholders in the pharmaceutical and biotechnology industry. Additionally, novel modalities, including recombinant proteins, vaccines, cell and gene therapies, are growing faster than any other segment of medicine. This has led the biologics to be on the verge of surpassing small molecules in terms of revenues.
Fundamental Advancements in the Biopharmaceutical Manufacturing Processes
Conventional methods of biopharmaceutical manufacturing have been revolutionized by single-use technologies and its adoption is rapidly increasing for the production of biologics, including monoclonal antibodies, antibody drug conjugates, vaccines, cell and gene therapies. These disruptive innovations have also played a crucial role during the COVID-19 pandemic, facilitating rapid process development for manufacturing monoclonal antibodies-based drugs and vaccines. Closed plug-and-play solutions offered by single-use systems enable process intensification and continuous manufacturing, thereby becoming a preferred choice from developmental phases to commercial production of biologics.
Competitive Landscape of Biologics Contract Manufacturing Companies
The current landscape features the presence of over 305 biologics CMO offering contract manufacturing services for biologics. It is worth mentioning that there has been a substantial rise in the number of biologics manufacturing companies over the past decade, indicating a growing demand for capacities for manufacturing both novel and conventional drugs. Further, a significant proportion of the companies (30%) offer services for contract manufacturing of APIs and FDFs to biologic developers; notable examples include 3P Biopharmaceuticals, Afton Scientific, Baccinex, Celltrion, Eubiologics, Genovior, Hybio Pharmaceutical, Kanda BioTech, Lonza and Lubrizol Life Sciences.
Biologics Contract Manufacturing Market Size: North America to Hold the Largest Market Share
The global market for biologics contract manufacturing is estimated to be more than USD 19 billion in 2023. North America currently holds the largest share (34%) of the market, owing to the increasing R&D investments and number of clinical studies pertaining to the development of large molecules. Further, the biologics contract manufacturing market in Asia-Pacific is expected to grow at a relatively high CAGR of 11% during the forecast period. In terms of type of biologic manufactured, cell therapies capture around 40% share of the biologics contract manufacturing market by 2035.
Mammalian Cell Cultures is the Most Preferred Choice of Expression System Amongst Biologics Contract Manufacturing Players
Mammalian cell cultures have become the predominant expression system for the production of biopharmaceuticals, owing to their ability to effectively complete the post-translational modifications required for drug safety and efficacy. Over the past decade, the productivity of mammalian cell culture processes has grown dramatically due to improvements in cell line development.
Biologics CMO Made Considerable Investments to Build or Expand Manufacturing Facilities, With Some Global CMOs Re-evaluating Capacity Investments
The biologics CMO are actively adding new facilities in order to accommodate the growing biologics demand. These players are vigorously advancing their capabilities to serve as a fully integrated one-stop-shop by offering a range of biologic services, such as plasmid and viral vector development, fill-finish capabilities and gene delivery solutions. In order to expand the capabilities, expansion and investment in manufacturing facilities is essential. In June 2023, Enzene Biosciences announced the opening of its new state-of-the-art manufacturing facility in Pune, India with an aim to extend their drug development and manufacturing capabilities. In another announcement in March 2023, Biose expanded its live biotherapeutic product (LBP) process development and production capabilities with the opening of a new manufacturing facility in Massachusetts, US.
Post COVID-19 and considering the changes in macro-economic factors, some global biologics CMOs have recently re-evaluated their capacity expansions. In March 2023, Boehringer Ingelheim announced its plans to open a second biologics manufacturing facility in Austria is currently on hold.
Biologics Contract Manufacturing Market Trends Analysis: Increasing Partnerships and Collaborations to Foster Progress and Innovation
Stakeholders in the biopharmaceutical manufacturing industry have forged several partnerships in order to enhance their service portfolios. The growing preference for outsourcing bioprocessing operations is evident from the rise in partnership activity. It is worth highlighting that more than 61% of deals were inked in the last three years. Additionally, this segment of the global contract manufacturing market is growing rapidly and consistently after the COVID-19 pandemic. Notably, majority of the deals are focused on manufacturing and development of biologics, followed by mergers and acquisitions. This can be attributed to the incessant efforts of biologics CMO to further advance the development of their product offerings, across different phases. In May 2023, 3P Biopharmaceuticals signed an agreement with Zhittya Genesis Medicine to manufacture the latter company’s therapeutic candidate, for the treatment of neurodegenerative diseases (Parkinson’s disease). Further, in February 2023, AGC Biologics entered into an agreement with Genenta to manufacture cell therapy lentivirus-based product.
Leading CMOs Engaged in Biologics Contract Manufacturing Market
Examples of key biologics CMO (which have also been profiled in this market report) offering manufacturing services include (in alphabetical order) AGC Biologics, Boehringer Ingelheim, Catalent, Cell Therapies, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Kemwell Biopharma, Lonza, Miltenyi Biotec, Minaris Regenerative Medicine, Samsung Biologics, Sandoz, Vetter Pharma, WuXi Biologics. This market report includes an easily searchable excel database of all the biologics CMO and details on their manufacturing facilities worldwide.
Recent Developments in the Biologics Contract Manufacturing Market
Several recent developments have taken place in the global biologics contract manufacturing market. Some of these recent initiatives have been mentioned below. These developments, even if they took place post the release of this market report, substantiate the overall market trends that have been outlined in the analysis.
- In June 2023, Cell and Gene Therapy Catapult announced a technology licensing agreement with Albumedix, under which the latter company’s latest technology will be utilized for improving the manufacturing of viral vectors.
- In June 2023, Wuxi Biologics, offering end-to-end solutions to discover, develop and manufacture biologics, announced the expansion of its capacity for drug substances and drug products at its facility in Wuppertal, Germany.
- In March 2023, Samsung Biologics announced the construction of a fifth plant, at its facility in Incheon, South Korea, as part of its strategic expansion in response to increased market demand. Upon its completion, the plant is expected to hold a manufacturing capacity of 180,000 L and will expand the company’s total site capacity to 784,000 L by investing a sum of KRW 1.9 trillion.
- It is interesting to note that in February 2023, LOTTE BIOLOGICS announced the addition of three biomanufacturing plants in South Korea in order to produce a total of 360,000 L of antibody drugs. Such capacity additions are expected to drive biologics contract manufacturing market growth, during the forecast period.
Scope of the Report
The market report presents an in-depth analysis, highlighting the capabilities of various biologics CMO engaged in this industry, across different geographies. Amongst other elements, the market research report features:
- A preface providing an introduction to the full market report, Biologics Contract Manufacturing Market, 2023-2035.
- An outline of the systematic research methodology adopted to conduct the study on the biologics contract manufacturing market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of the findings.
- An overview of economic factors that impact the overall biologics contract manufacturing market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
- An executive summary of the key insights captured during the research, offering a high-level view on the current state of the biologics contract manufacturing market and its likely evolution in the short to mid-to-long term.
- A brief introduction to the biologics contract manufacturing market, highlighting general overview of biopharmaceuticals, biopharmaceutical manufacturing processes, and various expression systems used for the development of different types of biotherapeutic products. Further, it features a brief overview of biologics contract manufacturing, along with a detailed discussion on the need for outsourcing within the biopharmaceutical industry. It also provides information on the challenges faced by players currently engaged in this market.
- An overview of the current market landscape of companies engaged in offering contract manufacturing services for biologics, including a detailed analysis based on several relevant parameters, such as year of establishment, company size (based on number of employees), location of headquarters, type of service offered (API and FDF manufacturing), type of biologic manufactured (antibody drug conjugates, antibodies, biosimilars, cell therapies, gene therapies, nucleic acids / oligonucleotides, plasmid DNA / viral vectors, proteins / peptides, vaccines and others), scale of operation (preclinical, clinical and commercial), type of expression system used (mammalian, microbial and others), type of bioreactor used (single-use and stainless steel) and mode of operation of bioreactor (batch, fed batch and continuous).
- An insightful analysis, highlighting the detailed landscape of the biopharmaceutical manufacturing facilities established across the key geographical regions (North America, Europe, Asia-Pacific and Rest of the World), highlighting the manufacturing hubs for biologics.
- Elaborate profiles of key biologics CMO based in North America that offer contract manufacturing services for biologics. Each profile features a brief overview of the company, along with details related to its biologic-related service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
- Elaborate profiles of key biologics CMO based in Europe that offer contract manufacturing services for biologics. Each profile features a brief overview of the company, along with details related to its biologic-related service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
- Elaborate profiles of key biologics CMO based in Asia-Pacific that offer contract manufacturing services for biologics. Each profile features a brief overview of the company, along with details related to its biologic-related service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
- A detailed discussion on the key enablers in this industry, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
- A case study on the growing global biosimilars market, highlighting the associated opportunities for biologics CMOs and CDMOs.
- A case study comparing the key characteristics of small and large molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
- A detailed discussion on the benefits and challenges associated with in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource the production operations.
- A qualitative analysis, highlighting various factors that need to be taken into consideration by biopharmaceutical developers while deciding whether to manufacture their respective products in-house or engage the services of a biologics CMO.
- A review of the various biopharmaceutical-focused manufacturing initiatives undertaken by top 12 big pharma players (shortlisted on the basis of 2022 revenues), highlighting trends across various parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of biologic manufactured.
- An analysis of the recent collaborations within the biologics contract manufacturing market, based on several relevant parameters, such as year of partnership, type of partnership, type of biologic manufactured, therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have taken place in this industry, during the period 2018-2023 (till July).
- A detailed analysis of the various mergers and acquisitions that have taken place within this industry, during the period 2018-2023 (till July), based on several relevant parameters, such as year of agreement, type of deal, geographical location of companies, type of acquisition, type of biologic manufactured and key value drivers.
- A detailed review of expansion initiatives undertaken by biologics CMO, during the period 2016-2023 (till July), along with information on several relevant parameters, such as year of expansion, purpose of expansion, type of biologic manufactured and location of expanded facility.
- An analysis of the recent developments within the biologics contract manufacturing market, highlighting information on the funding investments made during the period 2016-2022 (till July), along with information on the technology advancements related to biomanufacturing.
- An estimate of the overall installed capacity for the manufacturing of biopharmaceuticals, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity, based on size of manufacturer (small, mid-sized, and large and very large), type of expression system used (mammalian, microbial and others) and geography (North America, Europe, Asia-Pacific and Rest of the World).
- An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.
- A company size-wise, detailed analysis of the total cost of ownership for biologics CMO, during the period 2023-2043.
- A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT analysis, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT analysis on the overall biopharmaceutical industry.
- A case study on the virtual business model concept, along with its role in the overall biopharmaceutical industry. It also features a discussion on the advantages and risks / challenges associated with outsourcing operations from virtual service providers.
- An elaborate discussion on the future opportunities / trends within the biologics contract manufacturing market that are likely to influence the market growth of this industry over the forecast period.
One of the primary objectives of the presented market report is to conduct a comprehensive market forecast analysis, aiming to estimate both the current market size and the future opportunities within the biopharmaceutical contract manufacturing sector over the next decade. Drawing insights from various parameters, anticipated adoption trends, and validated through primary research, the report offers an informed estimate of the market's evolution throughout the forecast period from 2023 to 2035. It encompasses a detailed analysis of the likely distribution of current and projected opportunities within the biologics contract manufacturing market, considering various relevant factors. These factors include the type of service provided (API Manufacturing, FDF Manufacturing), the type of biologic manufactured (antibodies, cell therapies, vaccines, and other biologics), the expression system used (mammalian, microbial, and others), the scale of operation (preclinical/clinical and commercial), company size (small, mid-sized, large, and very large), key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America), and key players in the industry. To enhance the robustness of the model and address future uncertainties associated with key parameters, the report offers three market forecast scenarios: conservative, base, and optimistic. These scenarios represent different trajectories of the industry's evolution.
The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
- Chief Executive Officer, Mid-Sized Company, Scotland
- Chief Executive Officer and Co-Founder, Small Company, Slovenia
- Chief Technical Officer, Large Company, USA
- President and Chief Operating Officer, Mid-Sized Company, China
- Senior Director of Global Strategic Marketing, Large Company, USA
- Senior Director of Commercial Strategy and Market Insights, Large Company, USA
- Global Head of Sales and Marketing and Head of Business Development, Large Company, USA
- Business Development Manager, Small Company, Spain
- Manager Marketing and Sales, Mid-Sized Company, Germany
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
Key Companies Profiled
- AGC Biologics
- Boehringer Ingelheim
- Catalent
- Cell Therapies
- Charles River Laboratories
- FUJIFILM Diosynth Biotechnologies
- KBI Biopharma
- Kemwell Biopharma
- Lonza
- Miltenyi Biotec
- Minaris Regenerative Medicine
- Samsung Biologics
- Sandoz
- Vetter Pharma
- Wuxi Biologics
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 20Med Therapeutics
- 3P Biopharmaceuticals
- 3SBio
- 4D Pharma
- 4TEEN4 Pharmaceuticals
- 53Biologics
- Aalto Scientific
- AavantiBio
- AB2 Bio
- AbbVie
- Abcam
- AbCellera
- Abeona Therapeutics
- ABL Bio
- AbMax Biotechnology
- Abogen Biosciences
- Abpro
- Abzena
- AC Immune
- Acasti Pharma
- Accelerated Biosciences
- Accellta
- Accinov
- ACES Pharma
- Achilles Therapeutics
- ACT Therapeutics
- Acticor Biotech
- AcuraBio (formerly Luina Bio)
- Adagene
- AdAlta
- Adaptimmune
- AdaptVac
- Adare Pharma Solutions (formerly Aptalis Pharmatech)
- Adimmune
- Adimmune
- ADL BioPharma
- Advanced BioScience Laboratories
- Advanced Biotherapeutics Consulting
- Advanced Cell Technology and Engineering
- Advaxia Biologics
- Advaxis
- Advent Bioservices
- Advent International
- Affibody
- Affinita Biotech
- Affinity Life Sciences
- Afton Scientific
- AGC Biologics
- Agilis Biotherapeutics
- Airway Therapeutics
- Ajinomoto Bio-Pharma Services
- Akouos
- Akron Biotech
- Akshaya Bio
- Alaunos (formerly Ziopharm Oncology)
- Albumedix
- Alcami
- Alco Therapeutics
- Aldevron
- Alexion
- Alira Health
- AllCells
- Allele Biotechnology and Pharmaceuticals
- Allergy Therapeutics
- Allevi
- Alligator Bioscience
- Almac
- Almirall
- Alpine Immune Sciences
- Alteogen
- Altheia Science
- Altimmune
- Altor Bioscience
- Altruist Biologics
- AM-Pharma
- Amaran Biotechnology
- Amatsigroup (Acquired by Eurofins)
- AmbioPharma
- Amgen
- Ampersand Capital Partners
- Andelyn Biosciences
- Andes Biotechnologies
- Ankarys Therapeutics HebeCell
- ANL Bio
- Antabio
- Anthony Nolan
- Anthos Therapeutics
- apceth Biopharma
- Applied StemCell
- Aptevo Therapeutics
- AR BROWN
- Araris Biotech
- Aravive Biologics
- ARCALIS
- Arcellx
- Arch Biopartners
- ArchiMed
- ArcticZymes Technologies
- Arcturus Therapeutics
- Arcus Biosciences
- Arecor
- Argenx
- Arranta Bio (Acquired by Recipharm)
- Aruvant Sciences
- Asahi Kasei
- ASC Therapeutics
- Ascend Gene & Cell Therapies
- Asher Biotherapeutics
- Asimov
- Asklepios BioPharmaceutical
- ASLAN Pharmaceuticals
- Aspire Health Science
- Astero Bio
- Astorg
- AstraZeneca
- Asymchem
- Atara Biotherapeutics
- Athenex
- Athersys
- aTyr Pharma
- Aumgene Biosciences
- Aurinia Pharmaceuticals
- Austrianova
- AutekBio
- Autolomous
- Autolus Therapeutics
- Avectas
- AveXis
- Avid Bioservices
- Avril Biopharma
- Axcelead Drug Discovery Partners
- Axcellerate Pharma
- Axovant Gene Therapies
- Babraham Bioscience Technologies
- Baccinex
- Bachem
- Bacthera
- Batavia Biosciences
- Battelle
- Bavarian Nordic
- Baxter
- Baxter BioPharma Solutions
- Bayer
- Baylor College of Medicine
- Baylor Institute for Immunology Research
- Baylor Scott & White Research Institute
- BBI Solutions
- BCN Peptides
- Beam Therapeutics
- BeiGene
- Beijing Hetang Shenghua Medical Technology
- Beijing Kawin Technology Share-Holding
- Bennu Biotherapeutics
- Berkeley Lights
- BeRNA Therapeutics
- Bexion Pharmaceuticals
- Bhami Research Laboratory
- Bharat Biotech
- BIA Separations
- BianoGMP
- BIBITEC
- BiBo Pharma
- BINEX
- Bio Elpida
- Bio Farma
- Bio Immunitas
- Bio-Ess Laboratories
- Bio-Synthesis
- Bioasis
- BioCell
- BioCentriq
- BioCina
- Biocon
- BioConnection
- Biodextris
- Biofabri
- Biogen
- Bioingenium
- BioInno Bioscience
- Bioinova
- BioInvent International
- Biological E.
- BioMARC
- Biomay
- BioMeca
- Biomedical Advanced Research and Development Authority (BARDA)
- BiondVax Pharmaceuticals
- Bionova Scientific
- BioNTech
- Biopharma Global
- Bioqube Ventures
- Biosana Pharma
- BioSciencesCorp
- Biose Industrie
- BioSig Technologies
- Biosynth
- BioTechnique
- Biotechpharma UAB
- BioTime
- BioVaxys Technology
- BIOVECTRA
- Bioverativ
- Biovian
- Bioworkshops
- BioXcellence
- BioXpress Therapeutics
- BJ Bioscience
- BJP Laboratories
- Bliss Biopharmaceutical
- Bloom Science
- bluebird bio
- BlueJay Therapeutics
- Boehringer Ingelheim
- Boostimmune
- Bora Pharmaceuticals
- Boston Children’s Hospital
- Boston Institute of Biotechnology
- Boway Biotech Joint Antibody Engineering Technology Display and Service Center (a part of Thermo Fisher Scientific)
- Boyalife
- BPL Biologics
- BrainEver
- BrainStorm Cell Therapeutics
- Brammer Bio
- Brenus Pharma
- BriaCell Therapeutics
- Bright Peak Therapeutics
- Bristol Myers Squibb
- Bryllan
- BSP Pharmaceuticals
- Burrard Pharmaceuticals
- Buzzard Pharmaceuticals AB
- C3i
- Caeregen Therapeutics
- Caisson Biotech
- Caladrius Biosciences
- California Institute for Regenerative Medicine (CIRM)
- Calviri
- Calypso Biotec
- CANbridge Pharmaceuticals
- Cancer Research Technology
- Cancer Research UK (University of Southampton)
- Canton Biologics
- CanVirex
- Capricor Therapeutics
- Captozyme
- CARBOGEN AMCIS
- CaroGen
- Catalent
- Catamaran Bio
- CDR-Life
- Cedar Pharmaceuticals
- Ceidos
- Cell and Gene Therapy Catapult
- Cell Culture Company
- Cell One Partners
- Cell Therapies
- Cell-Easy
- Cellab
- Celladon
- Cellectis
- Cellenion
- CellGenix
- Cellin Technologies
- CELLINK
- Cellipoint Bioservices (Formerly Performance Cell Manufacturing)
- Celltrion
- CelluGen Biotech
- Cellular Biomedicine Group
- Cellular Therapeutics
- Cellusion
- CellVax Therapeutics
- CellVec
- Celonic
- Celsion
- Cenexi
- Centaur Biopharmaceutical
- Center for Breakthrough Medicines
- Center for Innovation in Advanced Development and Manufacturing
- Centers for Disease Control and Prevention
- Centre for Process Innovation
- CEPiA (Commercial & External Partnership, Industrial Affairs)
- Cerbios-Pharma
- Cerium Pharmaceuticals
- CEVEC Pharmaceuticals
- Changchun High-tech
- Charles River Laboratories
- Cheerland Biotechnology
- Chemomab Therapeutics
- ChemPartner
- Children's Hospital of Philadelphia (CHOP)
- Chime Biologics
- Chimeron Bio
- China Regenerative Medicine International (CRMI)
- CHINAGENE
- Chinese Peptide Company
- Chiome Bioscience
- CHO Pharma
- Chong Kun Dang
- Chord Therapeutics
- Chr. Hansen
- CiMaas
- Cipla
- CiRA Foundation
- Citryll
- Clean Biologics
- Clean Cells
- CMAB Biopharma
- CMC Biologics
- CMIC
- Coalition for Epidemic Preparedness Innovations(CEPI)
- Coave Therapeutics
- Cobra Biologics
- Codagenix
- Cognate BioServices
- Coherus BioSciences
- CoJourney
- Columbia University
- CombiGene
- Comprehensive Cell Solutions (CCS)
- Context Therapeutics
- Cook MyoSite
- CordenPharma
- Coretherapix
- CPC Scientific
- CPI
- CR Pharmaceutical
- CRC for Cell Therapy Manufacturing
- Creative Biogene
- Creative Biolabs
- CRISPR Therapeutics
- Cryoport
- CSBio
- CSL Seqirus
- CureCell
- CureVac
- Curia
- CyanVac
- Cytiva
- CytoDyn
- CytoSen Therapeutics
- Cytovance Biologics
- CyTuVax
- CZ Vaccines
- DAAN Biotherapeutics
- Daiichi Sankyo
- Dalton Pharma Services
- Danaher
- DanausGT Biotechnology
- DanDrit Biotech
- DaTaMabs
- Decibel Therapeutics
- Decipher Biosciences
- Delphi Genetics
- Denali Therapeutics
- Dendreon
- Dendreon Pharmaceuticals
- DeoBioSciences
- Department of Defense
- DiNAMIQS
- DiNAQOR
- DNDi
- Dongkook Pharmaceutical
- Dyadic International
- Dyax
- Educell
- Eikonoklastes Therapeutics
- EirGenix
- Eisai
- Eli Lilly
- Emendo Biotherapeutics
- Emercell
- Emergent BioSolutions
- Emerson
- ENCell
- Encure Biopharma
- Enimmune
- Enleofen Bio
- Enterobiome
- Enzene Biosciences
- Enzolytics
- ERC Belgium
- ERS Genomics
- Erytech Pharma
- Esco Aster
- Etinpro
- EuBiologics
- EUCODIS Bioscience
- EUFETS
- EUROAPI
- Eurocine Vaccines
- Eurofins
- Eurogentec
- Evanoa Bioscience
- EVER Pharma
- evitria
- Evologic Technologies
- Evotec
- EXCELLGENE
- Excellos
- ExCellThera
- Exelead
- Exelixis
- Exothera
- Expression Therapeutics
- FairJourney Biologics
- FamiCord
- Fapon Biopharma
- Farmabios
- Faron Pharmaceuticals
- FinVector
- Flagship Pioneering
- Flash Therapeutics
- FloDesign Sonics
- FluGen
- For?Robin
- Forecyte Bio
- Forge Biologics
- Formycon
- Forum for Innovative Regenerative Medicine
- Fred Hutchinson Cancer Research Center
- Freeline Therapeutics
- French Tech Sovereignty
- Fresenius Kabi
- FUJIFILM Diosynth Biotechnologies
- Fusion Antibodies
- GAIA BioMedicine
- Gamida Cell
- GBI (Formerly Goodwin Biotechnology)
- GC Cell
- GC Pharma
- GE Healthcare
- Gedeon Richter
- GemPharmatech
- GeneCraft
- GeneCure Biotechnologies
- Genenta Science
- Genentech
- GeneOne Life Sciences
- Geneos Therapeutics
- GeneQuantum Healthcare
- GeneQuine Biotherapeutics
- Genethon
- Genexine
- Genezen
- GenIbet Biopharmaceuticals
- Genmab
- Genome & Company
- Genopis
- Genovior
- Genprex
- GenScript ProBio
- GenSensor
- GentiBio
- Genuv
- GHO Capital
- GigaGen
- Gilead Sciences
- Ginkgo Bioworks
- Gladstone
- Gland Pharma
- GlycoSeLect
- Government of Canada
- Government of Europe
- Government Pharmaceutical Organization (Thailand)
- GP Pharm
- Grand River Aseptic Manufacturing (GRAM)
- Great Ormond Street Hospital for Children
- Great Point Partners
- Green Cross LabCell
- GreenLight Biosciences
- GreenPak Biotech
- Greffex
- Grenoble Hospital
- Griffith University
- GSK
- GTP Bioways (formerly VBI Therapeutics)
- GTP Technology
- Gubra
- HaemaLogiX
- HALIX
- Hangzhou Redox BIO
- Hanmi Pharmaceutical
- Hansa Biopharma
- Harbin Hou pu Tong tang Biotechnology
- Harbour BioMed
- Harpoon Therapeutics
- Harvard University
- HDT Bio
- Heidelberg Pharma
- Helixmith
- Helvetic BioPharma
- Hemogenyx
- Hepatic Cell Therapy Support
- Hikma Pharmaceuticals
- Hile Bio-Technology
- Hilleman Laboratories
- Histocell (Acquired by Noray)
- Hitachi
- HiTech Health
- HK inno.N
- Hong Kong Institute of Biotechnology
- Hookipa Biotech
- Horizon Discovery
- Horizon Pharma
- Horizon Therapeutics
- Houston Methodist Research Institute
- Hubei Yuyang Pharmaceutical
- Humanigen
- Hummingbird Bioscience
- Hybio Pharmaceutical
- Hycult Biotech
- HYGEIA
- I-Mab Biopharma
- IAVI
- IBC Generium
- IBI-Lorenzini
- Icagen
- Ichnos Sciences
- ID Pharma
- IDT Biologika
- Ikarovec
- Immatics
- Immune Pharmaceuticals
- Immunitas Therapeutics
- ImmunoCellular Therapeutics
- Immunocore
- ImmunoGenesis
- Immunome
- Immunomedics
- ImmunoTek Bio Centers
- Immutep (formerly Prima Biomed)
- Imperial College London
- Imperial Innovations
- In3Bio
- INADcure Foundation
- IncoCell Tianjin
- Indapta Therapeutics
- Indian Immunologicals
- IndyGeneUS AI
- InflaRx
- Inhibrx
- InnoBation Bio
- Innoputix
- Innovative Biotech
- Innovative NeuroTechnologies
- InnovaVector
- Inovio Pharmaceuticals
- Inpac Probiotics
- INSERM-ANRS
- Insight68
- Institut Pasteur de Dakar
- Institute for Research
- Integrated DNA Technologies
- Integrity Bio
- IntellectiveBio
- International AIDS Vaccine Initiative
- International Consortium
- International Stem Cell Corporation
- International Vaccine Institute (IVI)
- Intervacc
- Invetech
- Iovance Biotherapeutics
- iProgen Biotech
- IQVIA
- IsoPlexis
- Italian Biochemical Institute Giovanni Lorenzini
- IUCT Oncopole
- Iveric Bio
- Ixaka
- JAFRAL
- Japan Tissue Engineering
- Japanese Society for Regenerative Medicine
- Jeneil Biotech
- JHL Biotech
- Jiangsu Puxin Biopharmaceutical
- Jikei University School of Medicine
- Jitsubo
- Jo Lab
- John Hopkins University
- Johnson & Johnson
- JOINN Biologics
- JOINN Laboratories
- Jubilant HollisterStier
- Juno Pharmaceuticals
- Junshi Biosciences
- Just Biotherapeutics
- Just-Evotec Biologics
- JW CreaGene
- JW Therapeutics
- KABS Laboratories
- KAHR Medical
- Kamat Pharmatech
- Kanaph Therapeutics
- Kanda BioTech
- Kaneka Eurogentec
- Karolinska Institutet
- KBI Biopharma
- Kemwell Biopharma
- Kiadis Pharma
- Kidswell Bio
- Kineta
- Kite Pharma
- Kodiak Sciences
- KOLON Life Science
- KP Pharmaceutical Technology
- KPC
- KriSan Biotech
- KUBio
- Kun Tuo Medical Research and Development
- KURE.AI
- Kytopen
- L-GAM
- Labcorp
- Laboratorios Zepol
- Lacer
- LakePharma
- LamKap Bio
- LAMPIRE Biological Laboratories
- Landau Biotechnology
- LaNova Medicines
- Lava Therapeutics
- Leads Biolabs
- Leanbio
- LEUKOCARE
- Levena Biopharma
- Li Xiulan
- Life Biosciences
- Lifera
- LIfT BioSciences
- Liminal BioSciences (formerly Prometic Life Sciences)
- Limula
- lino Biotech
- Lipum
- List Biological Laboratories
- LNC Therapeutics
- LogicBio Therapeutics
- Lokon Pharma
- LongBio
- Lonza
- LOTTE BIOLOGICS
- Lubrizol Life Science
- LucasPye BIO
- Luina Bio
- Lupin
- Lykan Bioscience
- Lyophilization Services of New England
- Lyophilization Technology
- Lysogene
- Mab-Venture Biopharma
- Mabion
- MabPlex
- MAbSilico
- mAbxience
- MacroGenics
- Malvern Panalytical
- Massachusetts Eye and Ear
- Massachusetts Institute of Technology (MIT)
- MassBiologics
- MaSTherCell
- Matica Biotechnology
- Max Planck Society, University Medical Center Göttingen
- MaxiVAX
- Mayo Clinic
- MD Anderson Cancer Center (The University of Texas)
- Medeor Therapeutics
- Medical Technologies Innovation Facility
- Medigene
- MedImmune
- MEDINET
- MEDIPOST
- Medisun Holdings
- Medix Biochemica
- Meissa Vaccines
- Memo Therapeutics
- Menarini Biotech
- Mendus
- Merck
- Merck Millipore
- Meridian BioGroup
- Meridian Bioscience
- Meridian Life Science
- Mesoblast
- Metastagen
- Meteoric Biopharmaceuticals
- MGB Biopharma
- Microbiome Therapeutics Innovation Group (MTIG)
- MicroBiopharm Japan
- MicrofluidX
- Mila’s Miracle Foundation
- MilliporeSigma
- Milner Therapeutics Institute
- Miltenyi Biotec
- Minaris Regenerative Medicine
- Minneapolis Medical Research Foundation
- Mitsubishi Gas Chemical Company
- mk2 Biotechnologies, Technical University of Munich (TUM)
- Moderna
- Molecular Partners
- Morphotek
- Multispan
- Multiverse Pharma
- Mundipharma
- Mustang Bio
- Mycenax Biotech
- Mylab Discovery Solutions
- Myrtelle
- NAGASE & CO.
- Najít Technologies
- Namocell
- Nan Fung
- Nanotein Technologies
- Naobios
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Center for Regenerative Medicine
- National Health Research Institutes
- National Heart, Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Health (NIH)
- National Resilience
- Nature Technology
- Navrogen
- NBE-Therapeutics
- Neogen TC
- NeoProgen
- Neovacs
- NeoVentures Biotechnology
- Neuland Laboratories
- NeuroFx
- NEUWAY Pharma
- NextCell Pharma
- Nikon CeLL innovation
- Nitto Avecia
- NIZO
- Nobelpharma
- North Carolina State University
- Northway Biotech
- Nouscom
- NovalGen
- Novartis
- Novasep
- Novavax
- Novex Innovations
- NovoCodex Biopharmaceuticals
- Novozymes
- Nucleus Biologics
- Numab Therapeutics
- Nykode Therapeutics
- NYU Langone Health
- OBI Pharma
- OBiO Technology
- Octane Biotech
- Ocugen
- Oculogenex
- Odimma Therapeutics
- Odylia Therapeutics
- Ology Bioservices
- Olon
- Omeros
- OmniaBio
- Oncodesign
- OncoOne
- OncoQuest
- OncoResponse
- OncoVent
- Ondek
- Ono Pharmaceutical
- OPM Biosciences
- Oragenics
- Orchard Therapeutics
- Orgenesis
- Osaka University
- OSE Immunotherapeutics
- Osivax
- Otsuka Pharmaceutical
- Oxford BioMedica
- Oxford BioTherapeutics
- Oxford Genetics
- Oxford MEStar
- OXGENE
- Pace Life Sciences
- PackGene Biotech
- PaizaBio
- Pall
- Panacea Biotec
- Panacea Pharmaceuticals
- PanCELLa
- Panolos Bioscience
- Paragon Bioservices
- Paras Biopharmaceuticals
- Parker Institute for Cancer Immunotherapy
- Passage Bio
- PATH
- PCI Pharma Services
- PCT
- Peking University Biologics
- Peter MacCallum Cancer Centre
- Petrovax
- Pfizer
- Pfizer CentreOne
- Phanes Therapeutics
- PharmAbcine
- PharmaBio
- PharmaCell
- Pharmadule Morimatsu
- PharmaZell
- Pharmicell
- PhaseBio Pharmaceuticals
- pHion Therapeutics
- Pierre Fabre
- Pinteon Therapeutics
- Pionyr Immunotherapeutics
- Piramal Pharma Solutions
- PlasmidFactory
- Pluristyx
- Polaris Pharmaceuticals
- Polpharma Biologics
- POLYGON Therapeutics
- Polyplus
- POLYVAC
- Portola Pharmaceuticals
- Porton Advanced Solutions
- Precirix
- Precision NanoSystems
- Prestige Biologics
- Prevail Therapeutics
- Probiodrug
- ProBioGen
- Profacgen
- Profectus BioSciences
- Prokarium
- Propanc Biopharma
- Proteon Therapeutics
- ProteoNic
- Protexin
- Provia Labs
- PsiVac
- PTC Therapeutics
- PX'Therapeutics
- Quantoom Biosciences
- Quell Therapeutics
- Quratis
- Radimmune Therapeutics
- Rani Therapeutics
- Rare Trait Hope Fund
- Ray Therapeutics
- RD-Biotech
- Recipharm
- Refana
- ReForm Biologics
- REGENXBIO
- Regulus Therapeutics
- ReiThera
- Relief Therapeutics
- Remedium Bio
- ReNeuroGen
- Rentschler Biopharma
- Rentschler Fill Solutions
- Replicate Bioscience
- Resilience
- Resolution Therapeutics
- RevaTis
- Revolo Biotherapeutics
- RheinCell Therapeutics
- RiboBio
- Richter-Helm BioLogics
- River Vision Development
- Roche Diagnostics
- Rocket Pharmaceuticals
- Rokote Laboratories Finland
- RoosterBio
- Roslin Cell Therapies
- RoslinCT
- Royaltech Med
- RVAC Medicines
- Rznomics
- SAB Biotherapeutics
- Saiba Biotech
- Sam Chun Dang Pharm
- Samsung Bioepis
- Samsung Biologics
- San Raffaele Hospital
- SanBio
- Sandoz
- Sanofi
- Santen Pharmaceutical
- Sarepta Therapeutics
- Sartorius Stedim Biotech
- SBT Instruments
- Scancell
- SCD
- School of Chemical Engineering (part of University of Adelaide)
- Scientific Protein Laboratories
- ScinoPharm
- Scorpion Biological Services
- SD Biosensor
- Selecta Biosciences
- Selexis
- Serendex Pharmaceuticals
- Serum Institute of India
- Servier
- SGS
- Shandong Luoxin Pharmaceutical
- Shanghai Jiao Tong University
- Sheba Medical Center
- Shenyang Sino-German Equipment Park
- Shenzhen JYMed Technology
- Shilpa Biologicals
- Shire
- Shoreline Biosciences
- Showa Denko
- Siam Bioscience
- Siegfried
- SillaJen
- Simris
- Singota Solutions
- Singzyme
- Sino-German International Industrial Park
- Sinorda Biomedicine
- SIRION Biotech
- Sistemic
- SJL Partners
- SK bioscience
- Smart Cells Holdings
- Snapdragon Chemistry
- Sofpromed
- Solid Biosciences
- Sonnet BioTherapeutics
- Sorrento Therapeutics
- Southern RNA
- Spicona
- SpyBiotech
- ST Pharm
- Stand Up Therapeutics
- Stanford University School of Medicine
- STCube
- Stelis Biosource
- Stellar Biotechnologies
- Stemmatters
- Sterling Pharma Solutions
- STgen Bio
- Stoic Bio
- Stratophase
- Sumagen
- Sumitomo Dainippon Pharma
- Summa Life Sciences
- Sun Pharma
- Surface Oncology
- Surrozen
- Suzhou Kintor Pharmaceuticals
- Suzhou Royaltech Med
- SwiftScale Biologics
- Symbiosis Pharmaceutical Services
- Symphogen
- Synaffix
- SynCo Bio
- Synimmune
- Synklino
- Synpromics
- Synthace
- Synthelis
- T-knife
- TaiMed Biologics
- Taiwan Bio Therapeutics
- Taiwan Liposome Company
- Takara Bio
- Takeda
- Takeda Pharmaceuticals
- Taron Solutions
- TCR2 Therapeutics
- TechInvention Lifecare
- Tectron
- Telix Pharmaceuticals
- Tenboron
- TetraScience
- Teva Pharmaceuticals
- Tevogen Bio
- Texcell
- TG Therapeutics
- The Coalition for Epidemic Preparedness Innovations
- The International Vaccine Institute (IVI)
- The Leukemia & Lymphoma Society
- The Michael J. Fox Foundation
- The New Hope Research Foundation
- The Parker Institute for Cancer Immunotherapy (PICI)
- The Peter Doherty Institute for Infection and Immunity
- The University Medical Center Göttingen (UMG)
- The University of Adelaide
- The University of Manchester
- The US Department of Defence
- The Wistar Institute
- Themis
- Theracell Advanced Biotechnology
- Theragent
- Theramex
- Therapure Biopharma
- Theravectys
- Thermo Fisher Scientific
- ThermoGenesis (formerly known as Cesca Therapeutics)
- Thousand Oaks Biopharmaceuticals
- Tianjin Pharmaceutical
- TiGenix
- Tillotts Pharma
- Tizona Therapeutics
- Tmunity Therapeutics
- Tonix Pharmaceuticals
- Toregem BioPharma
- Touchlight
- Touchlight Genetics
- TRACON Pharmaceuticals
- TrakCel
- Transgene
- Translate Bio
- Transporin
- TranXenoGen
- Treadwell Therapeutics
- Trefoil Therapeutics
- Trellis Bioscience
- Tri-Institutional Therapeutics Discovery Institute
- Trianni
- Trieza Therapeutics
- TriLink BioTechnologies
- TRIO Pharmaceuticals
- Triphase Accelerator
- Trizell
- Tsinghua University Innovation Center for Immune Therapy
- TUBE Biopharmaceuticals
- TWi Pharmaceuticals
- Twist Bioscience
- TxCell
- U.S. Department of Defense
- uBriGene Biosciences
- UGA Biopharma
- UK Cystic Fibrosis Gene Therapy Consortium
- UK Dementia Research Institute
- UK Government
- Ultragenyx Pharmaceutical
- UNC Lineberger Comprehensive Cancer Center
- Unique Biotech
- Univercells
- Univercells Technologies
- University College London
- University of Aberdeen
- University of Birmingham
- University of California
- University of Leeds
- University of Pennsylvania
- University of Queensland
- University of Reading
- University of Sheffield
- University of South Australia
- University of Tokyo
- Uppsala BIO
- US Department of Defense
- US government
- Vaccine Manufacturing and Innovation Centre
- Vaccine Research Institute (VRI)
- Vaccitech
- Vaccizone
- ValenzaBio
- Valerius Biopharma
- Valneva
- Valo Health
- Valo Therapeutics
- Vanderbilt University Medical Center
- Vasculogics
- Vaxart
- VBI Vaccines
- VDDI Pharmaceuticals
- Vector BioMed
- VectorBuilder
- Vectron Biosolutions
- Veeva Systems
- Versameb
- Verseau Therapeutics
- Vertex Pharmaceuticals
- Vetter Pharma
- VGXI
- Vibalogics
- VIDO
- Vifor Pharma
- Vigene Biosciences
- Vineti
- Vir Biotechnology
- Viralgen
- Virchow Biotech
- Virion Therapeutics
- ViroCell Biologics
- Virovek
- Viscofan
- Vistria Group
- VIVEbiotech
- Voyager Therapeutics
- VVector Bio
- W.L. Gore & Associates
- WACKER
- Waisman Biomanufacturing
- Walvax Biotechnology
- Warburg Pincus
- Wheeler Bio
- Winclove Probiotics
- WuXi AppTec
- WuXi Biologics
- Wuxi Griffin
- Xbrane Biopharma
- Xenetic Biosciences
- XL-protein
- Xpress Biologics
- Xyphos Biosciences
- Yapan Bio
- Yinjia Biosciences
- Yposkesi
- Yuhan
- Zealand Pharma
- Zelluna Immunotherapy
- Zencore Biologics
- Zhejiang Hisun Pharmaceutical
- Zhejiang Teruisi Pharmaceutical
- Zhittya Genesis Medicine
- Zumutor Biologics
- Zymeworks
- ZyVersa Therapeutics
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 799 |
Published | December 2023 |
Forecast Period | 2023 - 2035 |
Estimated Market Value ( USD | $ 19.9 Billion |
Forecasted Market Value ( USD | $ 55.97 Billion |
Compound Annual Growth Rate | 9.0% |
Regions Covered | Global |